SNDX · CIK 0001395937
What Syndax Pharmaceuticals, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for SNDX. More may follow as additional filings are processed.
In its own words
What could break it.
Supplier concentration
- No in-house manufacturing — relies on a limited number of contract manufacturers (and partner Incyte) for all raw materials, API and finished product; commercial-manufacturing concentrationmedium
Syndax owns no manufacturing facilities for revumenib (Revuforj), axatilimab (Niktimvo) or entinostat and has no plans to build them. It relies entirely on third-party contract manufacturers — and on its partner Incyte — for all required raw materials, active pharmaceutical ingredients and finished product across preclinical, clinical and commercial supply, and it relies on a limited number of API suppliers, giving it explicit concentration risk in commercial manufacturing. With newly commercial products (Revuforj net revenue $124.8M in 2025) dependent on this outsourced, concentrated, single/limited-source chain, a supplier failure, quality issue or capacity shortfall could interrupt commercial supply. A genuine sole-source/manufacturing-concentration dependence (the Incyte supply relationship is also captured as an edge).
“the Company currently relies on a limited number of suppliers for the active pharmaceutical ingredients in its products. Accordingly, the Company has concentration risk associated with its commercial manufacturing.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Incyte leads the commercialization of axatilimab globally and we are co-commercializing Niktimvo in the United States.”
Cited →“We and Syndax have agreed to co-develop axatilimab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55 % of such costs and Syndax responsible for 45 % of such costs.”
Cited →
Its suppliers
“We currently rely on third-party contract manufacturers as well as Incyte for all of our required raw materials, active pharmaceutical ingredients and finished product for our preclinical research, clinical trials, and commercial supply.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch